GSK allots as much as $2B for "bolt-on acquisitions" in India

10/3/2011 | Wall Street Journal, The

GlaxoSmithKline is looking to spend between $500 million and $2 billion on smaller, "bolt-on acquisitions" in India to secure its position in emerging markets, CEO Andrew Witty said. He said GSK is not willing to overpay. "We already have an enviable brand in India so there is no need for us to pay a strategic premium," Witty said. "Others might need to do that, but we don't."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations